Drug Trial Radar · NCT03770936
Effect of Some Drugs on Liver Fibrosis
Last checked: Nov 20, 2026Latest source record: Dec 10, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
45
Planned (sponsor's estimate)
Start
Oct 1, 2018
Primary completion
Oct 2026
Study completion Nov 2027
Sponsor
- Lead sponsor
- Sherief Abd-ElsalamAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 10, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Effect of Some Drugs on Liver Fibrosis
Conditions
- Liver Fibroses
Interventions
CandesartanDrug
Candesartan 8 mg/day
RamiprilDrug
ramipril 1.25 mg/day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Fibroscan or APRI scoreTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sherief Abd-Elsalam
Tanta, Egypt · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.